8-KLeadership ChangesExhibits & Filings

IDEXX LABORATORIES INC /DE 8-K Report, Executive Changes (Mar 26, 2026)

Filed March 26, 2026For Securities:IDXX

Summary

IDEXX Laboratories, Inc. (IDXX) filed an 8-K on March 26, 2026, to report the departure of Dr. Nimrata Hunt, Executive Vice President of Global Strategy and Commercial, effective April 13, 2026. This departure was a mutual agreement, and Dr. Hunt will provide advisory services until July 13, 2026. The company has entered into a separation agreement that outlines the terms of her exit and advisory role. Investors should note the financial implications of Dr. Hunt's departure, including a separation package totaling approximately $2.24 million in salary continuation and target bonuses, along with COBRA premium costs, transition assistance, and tax/financial planning reimbursements. The company is classifying this as a termination without cause. The agreement also includes standard clauses like general release of claims, non-disparagement, and ongoing adherence to restrictive covenants. This filing primarily addresses a significant executive transition and associated costs.

Key Highlights

  • 1Departure of Executive Vice President, Global Strategy and Commercial, Dr. Nimrata Hunt, effective April 13, 2026.
  • 2Dr. Hunt to continue in an advisory capacity until July 13, 2026.
  • 3IDEXX to pay Dr. Hunt approximately $1.23 million in salary continuation over 104 weeks.
  • 4Aggregate target bonus payments of $984,000 to be paid over two years.
  • 5Additional separation benefits include COBRA premium support ($50,000), transition assistance ($10,000), and tax/financial planning reimbursement (up to $12,000).
  • 6Dr. Hunt's separation is classified as a termination without cause.
  • 7The separation agreement includes a general release of claims, non-disparagement, and continued adherence to restrictive covenants.

Frequently Asked Questions

The direct financial cost outlined in the separation agreement for Dr. Hunt includes approximately $1.23 million in salary continuation over 104 weeks, $984,000 in target bonus payments over two years, $50,000 for COBRA premiums, $10,000 for transition assistance, and up to $12,000 for tax and financial planning services. This totals approximately $2.286 million in direct payments and benefits.

The filing states that Dr. Hunt's position with IDEXX is being eliminated, which is the reason for classifying her separation as a termination without cause. This classification is a key factor in determining her eligibility for the specified separation benefits.

Dr. Hunt is obligated to provide advisory services on an as-needed basis until July 13, 2026. She has also entered into a general release of claims in favor of IDEXX, agreed to non-disparagement covenants, and will continue to be bound by existing restrictive covenants related to confidential information and intellectual property.

Vesting of Dr. Hunt's stock option, restricted stock unit, and performance stock unit awards will cease on her Final Employment Date (July 13, 2026). Any unvested awards will be forfeited. However, vested and exercisable stock options will remain exercisable according to their respective award agreements for a specified period.